Nicolson Andrew, Lewis Sheila A, Smith David F
Department of Neurology, Hope Hospital, Stott Lane, Salford M6 8HD, UK.
Neurology. 2004 Aug 10;63(3):568-70. doi: 10.1212/01.wnl.0000133214.78602.b3.
In this postlicensing surveillance study in a large unselected population, data were collected prospectively on all patients prescribed levetiracetam (LEV) at a regional epilepsy clinic over a 2-year period. Two hundred forty-five (69.2%) patients remained on LEV, with 8.8% achieving remission and some improvement in seizure control in 49.3%. Sedation was the most common adverse effect (10.7%), but mood disturbance was more likely to lead to discontinuation (4.8%). Cumulative probability of remaining on LEV at 12 months was 0.74 (95% CI 0.69 to 0.79). Factors predictive of a poorer retention were a greater number of previous antiepileptic drugs and a faster initial titration regimen.
在这项针对大量未经过筛选人群的上市后监测研究中，前瞻性收集了某地区癫痫诊所2年内所有处方左乙拉西坦（LEV）患者的数据。245名（69.2%）患者持续使用LEV，其中8.8%实现缓解，49.3%的患者癫痫控制有一定改善。镇静是最常见的不良反应（10.7%），但情绪障碍更有可能导致停药（4.8%）。12个月时持续使用LEV的累积概率为0.74（95%CI 0.69至0.79）。预测留存率较低的因素是既往使用抗癫痫药物数量较多以及初始滴定方案较快。
